Skip to main content
Premium Trial:

Request an Annual Quote

Finnish CRO Admescope Adopts Plexpress' TRAC Platform for ADME-Tox Services

Premium

This story was originally posted on May 16.

Admescope, a Helsinki, Finland-based contract research organization, will use Plexpress' TRAC platform to investigate in vitro drug interactions and preclinical ADME-tox responses, Plexpress said this week.

The CRO plans to first introduce Plexpress' assays targeting the cytochrome P450 family. Admescope expects demand for such services in part because of recent US Food and Drug Administration draft recommendations that suggest that CYP mRNA analysis could be more informative than measuring CYP activity for drug metabolism studies.

Admescope is the second CRO to adopt TRAC for ADME-tox this month. SBW, also based in Helsinki, announced recently that it would offer TRAC for high-throughput gene expression analysis to its clients in the pharmaceutical industry (BAN 5/8/2012). Like Admescope, SBW said it would initially offer Plexpress' TRAC cytochrome P450 family of multiplex assays.

Plexpress CEO Jari Rautio told BioArray News following the SBW deal that the firm plans a series of CRO collaborations, and that such partnerships will "form a core component" of the firm's ongoing business strategy."

Like SBW and Admescope, Plexpress is located in Helsinki. The privately held company was established in 2007 to commercialize TRAC, which stands for Transcript Analysis with the aid of Affinity Capture. According to the firm, TRAC relies on a set of amplifiable detection probes and biotinylated oligo-capture probes that are hybridized in solution. The resulting sandwich hybrids are collected on magnetic streptavidin-coated microparticles and washed. The hybridized probes are then eluted and detected with laser-induced fluorescence and capillary electrophoresis. TRAC has been adapted to work in a 96-well format, allowing users to profile the expression of 30 genes in each well.

Plexpress currently provides a Human ADMET service for measuring gene expression levels of cytochrome P450-encoding genes and other genes associated with drug metabolism, according to its website. Rather than building its own sales force to support the platform, it has instead focused on expanding its service offering via CROs, which offer TRAC using kits provided by Plexpress, according to Rautio. The company has positioned TRAC as an alternative to quantitative PCR and traditional gene expression arrays, citing advantages in cost and scalability.

Financial terms of the recent deal with Admescope were not discussed.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.